Sobi launch Doptelet® (avatrombopag) in Europe
Sobi™ Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced (11/04/20) the commercial launch of Doptelet® (avatrombopag) in Europe, with the United Kingdom as the first country for launch. Doptelet is a thrombopoietin receptor agonist (TPO-RA) approved for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.
- From Sobi Press Release